NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 22 mins

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.78+0.68 (+1.33%)
At close: 4:00PM EDT
People also watch
ALKSPGNXLGNDNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close51.10
Open51.69
Bid42.00 x 100
Ask0.00 x
Day's Range51.37 - 52.18
52 Week Range37.35 - 55.15
Volume849,957
Avg. Volume1,247,406
Market Cap4.51B
Beta1.76
PE Ratio (TTM)-31.77
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting

    SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston. Additionally, two posters representing additional data from several clinical trials of INGREZZA will be presented, including an analysis of its pharmacologic characteristics. "We are very pleased to present additional robust data from the largest ever clinical program in tardive dyskinesia at this year's American Academy of Neurology Annual Meeting," said Chris O'Brien, M.D., FAAN, Chief Medical Officer at Neurocrine.

  • Zacks6 days ago

    Should You Make a Bet on the Healthcare Stocks?

    The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.

  • Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
    Zacks11 days ago

    Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

    Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).